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Background
Imaging in patients with renal insufficiency (RI) is limited
by contrast induced nephropathy and nephrogenic sys-
temic fibrosis. Ferumoxytol is an FDA approved superpara-
magnetic iron compound used for the treatment of anemia
in patients with renal insufficiency. Previous studies of its
use as an MRA contrast agent did not assess safety, were
not conducted in patients with RI, and were limited by
small sample size. We characterized the safety, image qual-
ity, and clinical impact of ferumoxytol-enhanced MRA
(FeMRA) in patients with RI as compared to gadolinium-
enhanced MRA (GeMRA) in patients without RI.
Methods
All patients referred for cardiovascular MRA at two institu-
tions between June 2009 and February 2012 were entered
into a prospective database. Patients with chronic RI,
defined as GFR < 30 ml/min, or acute kidney injury were
eligible for FeMRA. Prior to FeMRA, patients underwent
screening for iron overload via history and serum iron stu-
dies or T2* imaging. Images were assessed quantitatively
and qualitatively on a 1-5 Likert scale by two blinded read-
ers. Three-month follow-up for adverse events, further
imaging, and subsequent endovascular or surgical interven-
tions was obtained. A comparator group was chosen at
random from patients without RI who underwent GeMRA
for similar indications during the same time period (n=70).
Results
Of 6198 patients undergoing MRA, 203 were eligible for
FeMRA. Of these, 7 patients were excluded due to ele-
vated ferritin or low T2*, 2 did not provide consent for
FeMRA, and 39 underwent GeMRA based on attending
preference. Of 155 FeMRA scans, symptomatic adverse
events (IV site reaction, nausea/vomiting) occurred in
1.3% of FeMRA, and 0.4% had symptomatic hypotension
requiring IV fluid administration. Subjective image qual-
ity was similar between FeMRA and GeMRA (4.6 ± 0.6
[n=155] vs. 4.6 ± 0.6 [n=70], p = 0.72). Contrast-to-
noise ratio was also indistinguishable between FeMRA
and GeMRA (45.2 ± 41.6 [n=30] vs. 45.9 ± 23.8 [n=18],
p=0.94). FeMRA and GeMRA were of sufficient diagnos-
tic quality to prevent further imaging in 76.2% and 70%
of patients, respectively (p=0.12; 95% CI of odds ratio
0.86 - 3.62). FeMRA and GeMRA guided subsequent
endovascular or surgical intervention in 33.5% and
42.9% of patients, respectively (p=0.23; 95% CI of odds
ratio 0.78 - 2.75).
Conclusions
FeMRA has an acceptable safety profile, excellent image
quality, and impacts clinical management in patients
with RI similarly to GeMRA in patients with preserved
renal function. Ferumoxytol represents a currently avail-
able and potentially effective MRA contrast agent for
patients with RI.
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Figure 1 Ferumoxytol thoracoabdominal MRA (A) in a patient with GFR < 30 and gadolinium thoracoabcominal MRA (B) in the same patient 2
months earlier. Ferumoxytol abdominal aortic MRA in a patient with GFR < 30 (Panel C) and gadolinium abdominal aortic MRA in the same
patient 2 months earlier (Panel D). Ferumoxytol carotid MRA (E) and gadolinium carotid MRA (F) in the same patient 1 year earlier.
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